| |
Wednesday, March 26, 2025 | 12pm ET / 9am PT Join us for this exclusive webinar to gain actionable insights from industry experts on the top challenges of HCP engagement and latest strategies for driving commercial success. Register today.
|
|
Today’s Big NewsMar 17, 2025 |
|
Thursday, March 27, 2025 | 11am ET / 8am PT This webinar will explore the growing need for process intensification in bioprocessing as a crucial step toward enhancing efficiency and sustainability. Join us to gain valuable insights into overcoming challenges related to bioprocess scale-up, including the adaptation of novel bioreactors, media formulations, and cell culture practices. Register now.
|
|
| By James Waldron AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform. |
|
|
|
By Zoey Becker The company revealed a plan to shutter the site back in March of 2022. Now, more than 150 staffers are set to lose their jobs throughout the rest of 2025 and into 2026. |
By Conor Hale The FDA is urging dialysis providers to conserve their supplies of blood flow lines, amid a shortage of the specialized tubing that the agency expects will continue for at least six months. |
By Gabrielle Masson In a late-stage trial of patients with multiple types of blood cancers, Orca Bio’s allogeneic T-cell immunotherapy doubled the rate at which patients survived without developing chronic graft-versus-host disease. Investigators compared the cell therapy against conventional allogeneic stem cell transplants. |
|
Thursday, April 3, 2025 | 11am ET / 8am PT Join us for an insightful webinar on the latest advancements in cell and gene therapy, focusing on the innovative Cas9-CLIPT (Cleaved, Linearized with Protein Template) technology. Learn more about this groundbreaking technology designed to improve the efficiency of genome editing. Register now.
|
|
By Darren Incorvaia Apriori Bio has become the latest Flagship Pioneering-backed biotech to shed staff, cutting 15 workers to leave 21 still employed at the vaccine-focused firm. |
By Eric Sagonowsky,Angus Liu,Fraiser Kansteiner,Andrea Park,Kevin Dunleavy,Zoey Becker Johnson & Johnson, Amgen, Regeneron, Novartis and other Big Pharma players are facing down sizable U.S. losses of exclusivity in 2025. |
By Conor Hale David Pacitti is leaving the imaging giant to become CEO of Avanos Medical, after its chief announced his retirement late last year. |
By Darren Incorvaia After some earlier data sparked questions from analysts, Avidity Biosciences has released more data for its RNA-based Duchenne muscular dystrophy candidate. |
By Nick Paul Taylor Novo Nordisk has been accepted back into the fold. Two years after suspending Novo, the Association of the British Pharmaceutical Industry reinstated the Danish drugmaker after seeing “clear, significant and sustained improvements.” |
By Nick Paul Taylor Incyte has delivered a pair of pivotal wins for an oral JAK inhibitor in an inflammatory skin condition. But with the placebo-adjusted response rate down on phase 2, the results drew unfavorable comparisons to rival data and triggered a 15% drop in the biotech’s share price. |
By James Waldron Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug conjugate linker platform. |
By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Zoey Becker,Kevin Dunleavy In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. |
By Andrea Park For the last year, AstraZeneca has been urging sports fans to “Get Body Checked Against Cancer” in a campaign launched in collaboration with the NHL. It’s now ramping up the screening push with a starry new partnership. |
Fierce podcastsDon’t miss an episode |
| This week on "The Top Line," we dissect the unprecedented revenue growth enjoyed by many major pharma companies in 2024’s fourth quarter. |
|
|---|
|
|
| WhitepaperRead about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperDiscover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
| WhitepaperDevelop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| |
|
